Disease modifying
Showing 1 - 25 of >10,000
Parkinson Disease Trial in Roma (Physical activity training)
Recruiting
- Parkinson Disease
- Physical activity training
-
Roma, ItalyFlavia Torlizzi
Apr 4, 2023
Multiple Sclerosis Trial in Melsbroek
Completed
- Multiple Sclerosis
-
Melsbroek, Vlaams Brabant, BelgiumNationaal MS center
Apr 17, 2023
Multiple Sclerosis COVID-19/Vaccination Treated With Ofatumumab
Completed
- Multiple Sclerosis
-
East Hanover, New JerseyNovartis
Jul 14, 2023
Czech Pharmaco-epidemiological Study on Disease Modifying Drugs
Completed
- Multiple Sclerosis
- interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
-
Prague, CzechiaIMPULS Endowment Fund
Mar 7, 2023
Kesimpta Pregnancy and Infant Safety Study Using Real World Data
Not yet recruiting
- Multiple Sclerosis
- Multiple sclerosis disease modifying drug
- (no location specified)
Nov 27, 2023
Parkinson's Disease Trial (Lithium aspartate)
Not yet recruiting
- Parkinson's Disease
- Lithium aspartate
- (no location specified)
Oct 27, 2023
Long Term Trajectories of SMA Patients Receiving or Not
Recruiting
- Spinal Muscular Atrophy
-
Genova, Italy
- +4 more
Mar 2, 2023
Describe Switching FromFirst- or Second-line Disease Modifying
Not yet recruiting
- Multiple Sclerosis, Relapsing-Remitting
- (no location specified)
Dec 12, 2022
Antibody Response to COVID19 Vaccination in Multiple Sclerosis
Completed
- Multiple Sclerosis
- Covid19
-
Livingston, New JerseySaint Barnabas Medical Center
Aug 16, 2022
Tofacitinib and Biologic Disease Modifying Antirheumatic Drugs
Completed
- Arthritis, Rheumatoid
-
Tokyo, JapanPfizer
Nov 28, 2022
Post-COVID-19 Syndrome Trial in Geneva (Temelimab 54mg/kg, Placebo)
Not yet recruiting
- Post-COVID-19 Syndrome
- Temelimab 54mg/kg
- Placebo
-
Geneva, SwitzerlandGeneva University Hospital
Aug 9, 2022
Disease Modifying Genes in Severe Asthma
Active, not recruiting
- Asthma
-
New York, New YorkNYU School of Medicine
Jan 11, 2022
Parkinson's Disease Trial in London (Exenatide extended release 2mg (Bydureon))
Active, not recruiting
- Parkinson's Disease
- Exenatide extended release 2mg (Bydureon)
-
London, United KingdomUniversity College London Hospital
May 18, 2022
Chronic Rhinosinusitis With Nasal Polyps Trial (Mepolizumab 100 MG Injection)
Not yet recruiting
- Chronic Rhinosinusitis With Nasal Polyps
- Mepolizumab 100 MG Injection
- (no location specified)
Jun 16, 2023
Discontinuation of Disease Modifying Therapies in Multiple
Completed
- Multiple Sclerosis
-
Aurora, Colorado
- +9 more
Dec 15, 2022
Mild Cognitive Impairment, Cognitive Decline, Healthy Aging Trial in Iowa City (melatonin, )
Recruiting
- Mild Cognitive Impairment
- +2 more
- melatonin
- placebo
-
Iowa City, IowaUniversity of Iowa Hospitals & Clinics
Feb 10, 2022
Long-Term Safety of Vumerity and Tecfidera in Multiple Sclerosis
Not yet recruiting
- Multiple Sclerosis
- Diroximel Fumarate
- +2 more
- (no location specified)
Mar 2, 2023
MAP THE SMA:Machine-learning Based Algorithm to Predict
Not yet recruiting
- Spinal Muscular Atrophy
- disease modifying treatments
- (no location specified)
Mar 14, 2023
Rheumatoid Arthritis Trial in Dhaka (Vitamin D3)
Completed
- Rheumatoid Arthritis
- Vitamin D3
-
Dhaka, BangladeshBSMMU
Feb 1, 2022
Amyotrophic Lateral Sclerosis Trial in France (Deferiprone, Placebo Oral Tablet)
Active, not recruiting
- Amyotrophic Lateral Sclerosis
- Deferiprone
- Placebo Oral Tablet
-
Angers, France
- +14 more
Nov 4, 2022
Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified
Not yet recruiting
- Coronary Artery Disease
- Shockwave Medical Coronary IVL System
- (no location specified)
Mar 2, 2023
The 'Wearing Off' Effect of DMT
Recruiting
- Multiple Sclerosis
- ocrelizumab
- +2 more
-
Basel, SwitzerlandNovartis Investigative Site
Jan 24, 2023
Parkinson Disease, GBA Gene Mutation Trial in Milan, Naples, Pavia (Ambroxol Hydrochloride, Placebo)
Recruiting
- Parkinson Disease
- GBA Gene Mutation
- Ambroxol Hydrochloride
- Placebo
-
Milan, Italy
- +2 more
Mar 10, 2022
Multiple Sclerosis Trial in Cambridge (Metformin and clemastine in combination, Placebo)
Recruiting
- Multiple Sclerosis
- Metformin and clemastine in combination
- Placebo
-
Cambridge, United KingdomAddenbrooke's Hospital
Jun 14, 2022
